Xu Xu1,2, Christopher Krumm1,2, Jae-Seon So1,3, Curtis J Bare2, Corey Holman2, Jesper Gromada4, David E Cohen2, Ann-Hwee Lee1,4. 1. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY. 2. Division of Gastroenterology and Hepatology, Joan & Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY. 3. Department of Medical Biotechnology, Dongguk University Gyeongju, Gyeongju-si, Korea. 4. Regeneron Pharmaceuticals, Tarrytown, NY.
Abstract
Integrated stress response (ISR) is a signaling system in which phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) by stress-specific kinases and subsequent activation of activation transcription factor (ATF) 4 help restore cellular homeostasis following exposure to environmental stresses. ISR activation has been observed in metabolic diseases, including hepatic steatosis (HS), steatohepatitis (SH), and insulin resistance (IR), but it remains unclear whether ISR contributes to disease pathogenesis or represents an innate defense mechanism against metabolic stresses. Constitutive repressor of eIF2α phosphorylation (CReP) is a critical regulatory subunit of the eIF2α phosphatase complex. Here, we show that CReP ablation causes constitutive eIF2α phosphorylation in the liver, which leads to activation of the ATF4 transcriptional program including increased fibroblast growth factor 21 (FGF21) production. Liver-specific CReP knockout (CRePLKO ) mice exhibited marked browning of white adipose tissue (WAT) and increased energy expenditure and insulin sensitivity in an FGF21-dependent manner. Furthermore, CRePLKO mice were protected from high-fat diet (HFD)-induced obesity, HS, and IR. Acute CReP ablation in liver of HFD-induced obese mice also reduced adiposity and improved glucose homeostasis. Conclusion: These data suggest that CReP abundance is a critical determinant for eIF2α phosphorylation and ensuing ISR activation in the liver. Constitutive ISR activation in the liver induces FGF21 and confers protection from HFD-induced adiposity, IR, and HS in mice. Augmenting hepatic ISR may represent a therapeutic approach to treat metabolic disorders.
Integrated stress response (ISR) is a signaling system in which phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) by stress-specific kinases and subsequent activation of activation transcription factor (ATF) 4 help restore cellular homeostasis following exposure to environmental stresses. ISR activation has been observed in metabolic diseases, including hepatic steatosis (HS), steatohepatitis (SH), and insulin resistance (IR), but it remains unclear whether ISR contributes to disease pathogenesis or represents an innate defense mechanism against metabolic stresses. Constitutive repressor of eIF2α phosphorylation (CReP) is a critical regulatory subunit of the eIF2α phosphatase complex. Here, we show that CReP ablation causes constitutive eIF2α phosphorylation in the liver, which leads to activation of the ATF4 transcriptional program including increased fibroblast growth factor 21 (FGF21) production. Liver-specific CReP knockout (CRePLKO ) mice exhibited marked browning of white adipose tissue (WAT) and increased energy expenditure and insulin sensitivity in an FGF21-dependent manner. Furthermore, CRePLKO mice were protected from high-fat diet (HFD)-induced obesity, HS, and IR. Acute CReP ablation in liver of HFD-induced obesemice also reduced adiposity and improved glucose homeostasis. Conclusion: These data suggest that CReP abundance is a critical determinant for eIF2α phosphorylation and ensuing ISR activation in the liver. Constitutive ISR activation in the liver induces FGF21 and confers protection from HFD-induced adiposity, IR, and HS in mice. Augmenting hepatic ISR may represent a therapeutic approach to treat metabolic disorders.
Authors: Heather P Harding; Yuhong Zhang; Huiquing Zeng; Isabel Novoa; Phoebe D Lu; Marcella Calfon; Navid Sadri; Chi Yun; Brian Popko; Richard Paules; David F Stojdl; John C Bell; Thore Hettmann; Jeffrey M Leiden; David Ron Journal: Mol Cell Date: 2003-03 Impact factor: 17.970
Authors: Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier Journal: Cell Metab Date: 2007-06 Impact factor: 27.287
Authors: Aude De Gassart; Bojan Bujisic; Léa Zaffalon; Laurent A Decosterd; Antonia Di Micco; Gianluca Frera; Rémy Tallant; Fabio Martinon Journal: Proc Natl Acad Sci U S A Date: 2015-12-29 Impact factor: 11.205
Authors: Kamal Albarazanji; Matthew Jennis; Cassandre R Cavanaugh; Wensheng Lang; Bhanu Singh; James C Lanter; James M Lenhard; Pamela J Hornby Journal: Am J Physiol Gastrointest Liver Physiol Date: 2019-03-28 Impact factor: 4.052
Authors: Kate J Claycombe-Larson; Amy Bundy; Elizabeth Black Lance; Diane C Darland; Shanon L Casperson; James N Roemmich Journal: J Nutr Biochem Date: 2021-09-11 Impact factor: 6.117
Authors: Daniel S Sinden; Corey D Holman; Curtis J Bare; Xiaolu Sun; Aravind R Gade; David E Cohen; Geoffrey S Pitt Journal: FASEB J Date: 2019-07-24 Impact factor: 5.834
Authors: Zhencheng Li; Mette Line Rasmussen; Jingwen Li; Carlos Henriquez-Olguin; Jonas Roland Knudsen; Agnete Bjerregaard Madsen; Eva Sanchez-Quant; Maximilian Kleinert; Thomas Elbenhardt Jensen Journal: Mol Metab Date: 2018-08-28 Impact factor: 7.422
Authors: Maria Ballester; Raquel Quintanilla; Francisco J Ortega; José C E Serrano; Anna Cassanyé; Maria Rodríguez-Palmero; José A Moreno-Muñoz; Manuel Portero-Otin; Joan Tibau Journal: Sci Rep Date: 2020-03-25 Impact factor: 4.379